You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMethylprednisolone
Accession NumberDB00959  (APRD00342)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA prednisolone derivative with similar anti-inflammatory action. [PubChem]
Structure
Thumb
Synonyms
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
1-dehydro-6alpha-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
delta(1)-6alpha-Methylhydrocortisone
Medrate
Medrol
Medrone
Methylprednisolon
Methylprednisolone
Methylprednisolonum
Metilprednisolona
Solomet
Urbason
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Depo-medrolinjection, suspension40 mg/mLintra-articular; intralesional; intramuscular; soft tissueCardinal Health1959-05-28Not applicableUs
Depo-medrolinjection, suspension40 mg/1intramuscularREMEDYREPACK INC.2013-04-10Not applicableUs
Depo-medrolinjection, suspension20 mg/mLintralesional; intramuscular; intrasynovial; soft tissuePharmacia And Upjohn Company Llc1959-05-28Not applicableUs
Depo-medrolinjection, suspension40 mg/mLintra-articular; intralesional; intramuscular; soft tissuePharmacia and Upjohn Company1959-05-28Not applicableUs
Depo-medrolinjection, suspension80 mg/mLintralesional; intramuscular; intrasynovial; soft tissueDispensing Solutions, Inc.1959-05-28Not applicableUs
Depo-medrolinjection, suspension40 mg/mLintralesional; intramuscular; intrasynovial; soft tissuePharmacia And Upjohn Company Llc1959-05-28Not applicableUs
Depo-medrolinjection, suspension80 mg/mLintra-articular; intralesional; intramuscular; soft tissueCardinal Health1959-05-28Not applicableUs
Depo-medrolinjection, suspension80 mg/mLintra-articular; intralesional; intramuscular; soft tissuePharmacia and Upjohn Company1959-05-28Not applicableUs
Depo-medrolinjection, suspension40 mg/mLintramuscularREMEDYREPACK INC.2013-06-11Not applicableUs
Depo-medrolinjection, suspension80 mg/mLintralesional; intramuscular; intrasynovial; soft tissuePharmacia And Upjohn Company Llc1959-05-28Not applicableUs
Depo-medrolinjection, suspension80 mg/mLintramuscularREMEDYREPACK INC.2014-09-12Not applicableUs
Depo-medrolinjection, suspension40 mg/mLintralesional; intramuscular; intrasynovial; soft tissueRebel Distributors Corp1959-05-28Not applicableUs
Depo-medrol (with Preservative) 20 mg/mlsuspension20 mgintra-articular; intralesional; intramuscular; intrasynovialPfizer Canada Inc1995-12-31Not applicableCanada
Depo-medrol (with Preservative) 40 mg/mlsuspension40 mgintra-articular; intralesional; intramuscular; intrasynovialPfizer Canada Inc1994-12-31Not applicableCanada
Depo-medrol (with Preservative) 80 mg/mlsuspension80 mgintra-articular; intralesional; intramuscular; intrasynovialPfizer Canada Inc1994-12-31Not applicableCanada
Depo-medrol 40 mg/mlsuspension40 mgintra-articular; intralesional; intramuscular; intrasynovialPfizer Canada Inc1960-12-31Not applicableCanada
Depo-medrol 80 mg/mlsuspension80 mgintra-articular; intralesional; intramuscular; intrasynovialPfizer Canada Inc1969-12-31Not applicableCanada
Medroltablet32 mg/1oralPharmacia And Upjohn Company Llc1957-10-24Not applicableUs
Medroltablet32 mg/1oralREMEDYREPACK INC.2011-10-11Not applicableUs
Medroltablet2 mg/1oralPharmacia And Upjohn Company Llc1957-10-24Not applicableUs
Medroltablet4 mg/1oralREMEDYREPACK INC.2013-02-19Not applicableUs
Medroltablet4 mg/1oralPharmacia And Upjohn Company Llc1957-10-24Not applicableUs
Medroltablet2 mg/1oralPharmacia And Upjohn Company Llc2013-09-20Not applicableUs
Medroltablet4 mg/1oralA S Medication Solutions Llc1957-10-24Not applicableUs
Medroltablet4 mg/1oralStat Rx USA1957-10-24Not applicableUs
Medroltablet16 mg/1oralPharmacia And Upjohn Company Llc1957-10-24Not applicableUs
Medroltablet4 mg/1oralA S Medication Solutions Llc1957-10-24Not applicableUs
Medroltablet8 mg/1oralPharmacia And Upjohn Company Llc1957-10-24Not applicableUs
Medrol 16 mgtablet16 mgoralPfizer Canada Inc1968-12-31Not applicableCanada
Medrol 4 mgtablet4 mgoralPfizer Canada Inc1960-12-31Not applicableCanada
Medrol Topical 0.25%cream2.5 mgtopicalPfizer Canada Inc1960-12-312006-08-02Canada
Methylprednisolonetablet32 mg/1oralGreenstone LLC2013-03-25Not applicableUs
Methylprednisolonetablet4 mg/1oralAltura Pharmaceuticals, Inc.2010-01-01Not applicableUs
Methylprednisolonetablet4 mg/1oralGreenstone LLC2011-10-11Not applicableUs
Methylprednisolonetablet4 mg/1oralKeltman Pharmaceuticals Inc.2007-09-14Not applicableUs
Methylprednisolonetablet4 mg/1oralLake Erie Medical DBA Quality Care Products LLC2012-02-09Not applicableUs
Methylprednisolonetablet8 mg/1oralGreenstone LLC2013-03-25Not applicableUs
Methylprednisolonetablet16 mg/1oralGreenstone LLC2013-03-25Not applicableUs
Methylprednisolone Acetate Injectable Suspension USPsuspension80 mgintra-articular; intramuscular; intrasynovial; soft tissue injectionSandoz Canada Incorporated2003-04-04Not applicableCanada
Methylprednisolone Acetate Injectable Suspension USPsuspension40 mgintra-articular; intramuscular; intrasynovial; soft tissue injectionSandoz Canada Incorporated2003-03-28Not applicableCanada
Methylprednisolone Acetate Injectable Suspension USP -(80mg/ml With Preservative)suspension80 mgintra-articular; intramuscular; intrasynovial; soft tissue injectionSandoz Canada Incorporated2003-04-10Not applicableCanada
Methylprednisolone Acetate Injectable Suspension USP -(40mg/ml With Preservative)suspension40 mgintra-articular; intramuscular; intrasynovial; soft tissue injectionSandoz Canada Incorporated2003-04-10Not applicableCanada
Methylprednisolone Sodium Succinate for Injectionpowder for solution125 mgintramuscular; intravenousTeva Canada Limited2000-03-01Not applicableCanada
Methylprednisolone Sodium Succinate for Injectionpowder for solution500 mgintramuscular; intravenousTeva Canada Limited2000-03-01Not applicableCanada
Methylprednisolone Sodium Succinate for Injectionpowder for solution1 gintramuscular; intravenousTeva Canada Limited2000-03-01Not applicableCanada
Methylprednisolone Sodium Succinate for Injectionpowder for solution5 gintramuscular; intravenousTeva Canada LimitedNot applicableNot applicableCanada
Methylprednisolone Sodium Succinate for Injectionpowder for solution40 mgintramuscular; intravenousTeva Canada Limited2000-03-01Not applicableCanada
Solu-medrolkit; powder for solution500 mgintramuscular; intravenousPfizer Canada Inc1970-12-31Not applicableCanada
Solu-medrolkit; powder for solution125 mgintramuscular; intravenousPfizer Canada Inc1997-06-102005-08-05Canada
Solu-medrolinjection, powder, for solution500 mg/mLintramuscular; intravenousPharmacia And Upjohn Company Llc1959-04-02Not applicableUs
Solu-medrolinjection, powder, lyophilized, for solution40 mg/mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2010-09-01Not applicableUs
Solu-medrolinjection, powder, for solution1 g/1intravenousREMEDYREPACK INC.2013-02-09Not applicableUs
Solu-medrolkit; powder for solution1 gintramuscular; intravenousPfizer Canada Inc2012-02-07Not applicableCanada
Solu-medrolinjection, powder, for solution1 g/mLintramuscular; intravenousPharmacia And Upjohn Company Llc1959-04-02Not applicableUs
Solu-medrolinjection, powder, for solution125 mg/mLintramuscular; intravenousCardinal Health1959-04-02Not applicableUs
Solu-medrolkit; powder1 gintramuscular; intravenousPfizer Canada Inc1994-12-312015-09-15Canada
Solu-medrolkit; powder for solution40 mgintramuscular; intravenousPfizer Canada Inc2012-01-11Not applicableCanada
Solu-medrolkit; powder for solution40 mgintramuscular; intravenousPfizer Canada Inc1997-06-102005-08-05Canada
Solu-medrolkitPharmacia And Upjohn Company Llc1959-04-02Not applicableUs
Solu-medrolinjection, powder, lyophilized, for solution125 mg/2mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2010-09-01Not applicableUs
Solu-medrolinjection, powder, for solution40 mg/1intravenousREMEDYREPACK INC.2013-04-15Not applicableUs
Solu-medrolinjection, powder, for solution40 mg/mLintramuscular; intravenousPharmacia And Upjohn Company Llc1959-04-02Not applicableUs
Solu-medrolinjection, powder, for solution125 mg/mLintramuscular; intravenousCardinal Health1959-04-02Not applicableUs
Solu-medrolinjection, powder, for solution40 mg/mLintramuscular; intravenousCardinal Health1959-04-02Not applicableUs
Solu-medrolkit; powder500 mgintramuscular; intravenousPfizer Canada Inc1995-12-312015-09-15Canada
Solu-medrolkit; powder for solution125 mgintramuscular; intravenousPfizer Canada Inc2012-01-18Not applicableCanada
Solu-medrolinjection, powder, for solution40 mg/mLintramuscular; intravenousCardinal Health1959-04-02Not applicableUs
Solu-medrolinjection, powder, for solution125 mg/mLintramuscular; intravenousUs Med Source, Llc2014-07-18Not applicableUs
Solu-medrolkit; powder125 mgintramuscular; intravenousPfizer Canada Inc1994-12-312015-09-15Canada
Solu-medrolinjection, powder, for solution40 mg/mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2010-04-01Not applicableUs
Solu-medrolinjection, powder, for solution125 mg/mLintramuscular; intravenousPharmacia And Upjohn Company Llc1959-04-02Not applicableUs
Solu-medrolinjection, powder, for solution125 mg/mLintramuscular; intravenousCardinal Health1959-04-02Not applicableUs
Solu-medrolpowder, for solution125 mg/mLintravenousREMEDYREPACK INC.2011-12-19Not applicableUs
Solu-medrolkit; powder for solution1 gintramuscular; intravenousPfizer Canada Inc1971-12-31Not applicableCanada
Solu-medrolkit; powder for solution500 mgintramuscular; intravenousPfizer Canada Inc2012-01-18Not applicableCanada
Solu-medrolinjection, powder, for solution500 mg/mLintramuscular; intravenousPharmacia And Upjohn Company Llc1959-04-02Not applicableUs
Solu-medrolinjection, powder, for solution40 mg/mLintramuscular; intravenousCardinal Health1959-04-02Not applicableUs
Solu-medrolkit; powder40 mgintramuscular; intravenousPfizer Canada Inc1994-12-312015-09-15Canada
Solu-medrolinjection, powder, for solution125 mg/mLintramuscular; intravenousA S Medication Solutions Llc1959-04-02Not applicableUs
Solu-medrolinjection, powder, for solution125 mg/mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2010-04-01Not applicableUs
Solu-medrolinjection, powder, for solution1 g/mLintramuscular; intravenousPharmacia And Upjohn Company Llc1959-04-02Not applicableUs
Solumedrol Inj 125mg Sterile Mixovialpowder for solution125 mgintramuscular; intravenous; rectalThe Upjohn Company Of Canada1969-12-311996-09-10Canada
Solumedrol Inj 40mg Sterile Mixovialpowder for solution40 mgintramuscular; intravenous; rectalThe Upjohn Company Of Canada1964-12-311996-09-10Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
A-methapredinjection, powder, lyophilized, for solution40 mg/mLintramuscular; intravenousHospira, Inc.2005-12-20Not applicableUs
A-methapredinjection, powder, lyophilized, for solution125 mg/2mLintramuscular; intravenousHospira, Inc.2005-12-20Not applicableUs
Methylprednisolonetablet4 mg/1oralREMEDYREPACK INC.2012-03-01Not applicableUs
Methylprednisolonetablet8 mg/1oralJUBILANT CADISTA PHARMACEUTICALS, INC.1997-10-31Not applicableUs
Methylprednisolonetablet16 mg/1oralKAISER FOUNDATION HOSPITALS2012-09-12Not applicableUs
Methylprednisolonetablet4 mg/1oralRebel Distributors Corp.1997-10-31Not applicableUs
Methylprednisolonetablet4 mg/1oralDispensing Solutions, Inc.1998-12-22Not applicableUs
Methylprednisolonetablet4 mg/1oralA S Medication Solutions Llc1998-12-22Not applicableUs
Methylprednisolonetablet4 mg/1oralProficient Rx LP1997-10-31Not applicableUs
Methylprednisolonetablet4 mg/1oralLake Erie Medical DBA Quality Care Products LLC1998-12-22Not applicableUs
Methylprednisolonetablet4 mg/1oralPreferred Pharmaceuticals, Inc.2013-09-03Not applicableUs
Methylprednisolonetablet4 mg/1oralREMEDYREPACK INC.2012-07-10Not applicableUs
Methylprednisolonetablet16 mg/1oralJUBILANT CADISTA PHARMACEUTICALS, INC.1997-10-31Not applicableUs
Methylprednisolonetablet4 mg/1oralbryant ranch prepack1997-10-31Not applicableUs
Methylprednisolonetablet4 mg/1oralSTAT Rx USA LLC1997-10-31Not applicableUs
Methylprednisolonetablet4 mg/1oralClinical Solutions Wholesale1997-10-31Not applicableUs
Methylprednisolonetablet4 mg/1oralPreferred Pharmaceuticals, Inc.2014-10-08Not applicableUs
Methylprednisolonetablet32 mg/1oralJUBILANT CADISTA PHARMACEUTICALS, INC.1997-10-31Not applicableUs
Methylprednisolonetablet4 mg/1oralUnit Dose Services1997-10-31Not applicableUs
Methylprednisolonetablet4 mg/1oralBlue Point Laboratories2013-08-02Not applicableUs
Methylprednisolonetablet4 mg/1oralSandoz Inc1997-10-31Not applicableUs
Methylprednisolonetablet4 mg/1oralPhysicians Total Care, Inc.2009-10-15Not applicableUs
Methylprednisolonetablet4 mg/1oralREMEDYREPACK INC.2012-09-05Not applicableUs
Methylprednisolonetablet4 mg/1oralJUBILANT CADISTA PHARMACEUTICALS, INC.1997-10-31Not applicableUs
Methylprednisolonetablet4 mg/1oralA S Medication Solutions1997-10-31Not applicableUs
Methylprednisolonetablet4 mg/1oralDIRECT RX2014-01-01Not applicableUs
Methylprednisolonetablet4 mg/1oralBreckenridge Pharmaceutical, Inc.2003-11-07Not applicableUs
Methylprednisolonetablet4 mg/1oralAmerican Health Packaging2013-11-25Not applicableUs
Methylprednisolonetablet4 mg/1oralQualitest Pharmaceuticals1998-12-22Not applicableUs
Methylprednisolonetablet4 mg/1oralAidarex Pharmaceuticals LLC1997-10-31Not applicableUs
Methylprednisolonetablet4 mg/1oralSTAT Rx USA LLC1997-10-31Not applicableUs
Methylprednisolonetablet4 mg/1oralPhysicians Total Care, Inc.1994-11-29Not applicableUs
Methylprednisolone Acetateinjection, suspension80 mg/mLintra-articular; intralesional; intramuscular; soft tissueTeva Parenteral Medicines, Inc.2005-03-08Not applicableUs
Methylprednisolone Acetateinjection, suspension40 mg/mLintra-articular; intralesional; intramuscular; soft tissueSandoz Inc2009-01-29Not applicableUs
Methylprednisolone Acetateinjection, suspension40 mg/mLintra-articular; intralesional; intramuscular; soft tissueTeva Parenteral Medicines, Inc.2005-03-08Not applicableUs
Methylprednisolone Acetateinjection, suspension80 mg/mLintralesional; intramuscular; intrasynovial; soft tissueTeva Parenteral Medicines, Inc.2006-10-31Not applicableUs
Methylprednisolone Acetateinjection, suspension40 mg/mLintra-articular; intralesional; intramuscular; parenteral; soft tissueRebel Distributors Corp2009-03-05Not applicableUs
Methylprednisolone Acetateinjection, suspension40 mg/mLintramuscular; intrasynovial; soft tissuePhysicians Total Care, Inc.2012-07-26Not applicableUs
Methylprednisolone Acetateinjection, suspension40 mg/mLintra-articular; intralesional; intramuscular; soft tissueProficient Rx LP2005-03-08Not applicableUs
Methylprednisolone Acetateinjection, suspension80 mg/mLintra-articular; intralesional; intramuscular; soft tissueSandoz Inc2009-01-29Not applicableUs
Methylprednisolone Acetateinjection, suspension40 mg/mLintralesional; intramuscular; intrasynovial; soft tissueTeva Parenteral Medicines, Inc.2006-10-31Not applicableUs
Methylprednisolone Acetateinjection, suspension40 mg/mLintra-articular; intralesional; intramuscular; parenteral; soft tissueSandoz Inc2009-03-05Not applicableUs
Methylprednisolone Acetateinjection, suspension80 mg/mLintra-articular; intralesional; intramuscular; parenteral; soft tissueRebel Distributors Corp2009-03-05Not applicableUs
Methylprednisolone Acetateinjection, suspension40 mg/mLintralesional; intramuscular; intrasynovial; soft tissueTeva Parenteral Medicines, Inc.2006-10-31Not applicableUs
Methylprednisolone Acetateinjection, suspension80 mg/mLintra-articular; intralesional; intramuscular; parenteral; soft tissueSandoz Inc2009-03-05Not applicableUs
Methylprednisolone Sodium Succinateinjection, powder, lyophilized, for solution40 mg/mLintramuscular; intravenousCardinal Health2004-11-30Not applicableUs
Methylprednisolone Sodium Succinateinjection, powder, lyophilized, for solution1 g/16mLintramuscular; intravenousFresenius Kabi USA, LLC2004-11-30Not applicableUs
Methylprednisolone Sodium Succinateinjection, powder, lyophilized, for solution2 g/1intramuscular; intravenousAuro Medics Pharma Llc2015-12-15Not applicableUs
Methylprednisolone Sodium Succinateinjection, powder, lyophilized, for solution125 mg/2mLintramuscular; intravenousCardinal Health2004-11-30Not applicableUs
Methylprednisolone Sodium Succinateinjection, powder, lyophilized, for solution40 mg/1intramuscular; intravenousAuro Medics Pharma Llc2015-12-15Not applicableUs
Methylprednisolone Sodium Succinateinjection, powder, lyophilized, for solution125 mg/1intramuscular; intravenousAuro Medics Pharma Llc2015-12-15Not applicableUs
Methylprednisolone Sodium Succinateinjection, powder, lyophilized, for solution40 mg/mLintramuscular; intravenousFresenius Kabi USA, LLC2004-11-30Not applicableUs
Methylprednisolone Sodium Succinateinjection, powder, lyophilized, for solution500 mg/1intramuscular; intravenousAuro Medics Pharma Llc2015-12-15Not applicableUs
Methylprednisolone Sodium Succinateinjection, powder, lyophilized, for solution125 mg/2mLintramuscular; intravenousFresenius Kabi USA, LLC2004-11-30Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Hybrisilgel10 mg/gtopicalBio Zone Laboratories, Inc.2010-05-05Not applicableUs
International Brands
NameCompany
MedrateNot Available
MedroneNot Available
MeproloneNot Available
SolometNot Available
UrbasonNot Available
Brand mixtures
NameLabellerIngredients
Depo-medrol With LidocainePfizer Canada Inc
Medrol Acne LotionPfizer Canada Inc
Methylprednisolone Sodium Succinate for Injection, USPHospira Healthcare Corporation
Neo-medrolPfizer Canada Inc
Neo-medrol Acne LotionPfizer Canada Inc
Physicians Ez Use M-predProficient Rx LP
Readysharp-p40Terrain Pharmaceuticals
Readysharp-p80Terrain Pharmaceuticals
Salts
Name/CASStructureProperties
Methylprednisolone acetate
ThumbNot applicableDBSALT001157
Methylprednisolone sodium succinate
ThumbNot applicableDBSALT001158
Categories
UNIIX4W7ZR7023
CAS number83-43-2
WeightAverage: 374.4706
Monoisotopic: 374.20932407
Chemical FormulaC22H30O5
InChI KeyInChIKey=VHRSUDSXCMQTMA-PJHHCJLFSA-N
InChI
InChI=1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1
IUPAC Name
(1S,2R,8S,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,8,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES
[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[[email protected]](O)[C@@]1([H])[C@@]2([H])C[[email protected]](C)C2=CC(=O)C=C[C@]12C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassHydroxysteroids
Direct Parent21-hydroxysteroids
Alternative Parents
Substituents
  • 21-hydroxysteroid
  • Progestogin-skeleton
  • Pregnane-skeleton
  • 20-oxosteroid
  • 17-hydroxysteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • 3-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • Delta-1,4-steroid
  • Tertiary alcohol
  • Cyclic alcohol
  • Alpha-hydroxy ketone
  • Cyclic ketone
  • Secondary alcohol
  • Ketone
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Carbonyl group
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationAdjunctive therapy for short-term administration in rheumatoid arthritis.
PharmacodynamicsMethylprednisolone and its derivatives, methylprednisolone sodium succinate and methylprednisolone acetate, are synthetic glucocorticoids used as antiinflammatory or immunosuppressive agents.
Mechanism of actionUnbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
Related Articles
AbsorptionOral bioavailability 80-99%
Volume of distributionNot Available
Protein binding78%
Metabolism

Hepatic

Route of eliminationNot Available
Half life1-3 hours
ClearanceNot Available
ToxicityLD50=2000 mg/kg (orally in rat)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9911
Blood Brain Barrier+0.9484
Caco-2 permeable-0.6404
P-glycoprotein substrateSubstrate0.7812
P-glycoprotein inhibitor INon-inhibitor0.7489
P-glycoprotein inhibitor IINon-inhibitor0.604
Renal organic cation transporterNon-inhibitor0.769
CYP450 2C9 substrateNon-substrate0.8415
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.7582
CYP450 1A2 substrateNon-inhibitor0.9473
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9513
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9167
Ames testNon AMES toxic0.9337
CarcinogenicityNon-carcinogens0.9529
BiodegradationNot ready biodegradable0.9492
Rat acute toxicity2.0025 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9459
hERG inhibition (predictor II)Non-inhibitor0.5985
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Pharmacia and upjohn co
  • Cadista pharmaceuticals inc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Heather drug co inc
  • Par pharmaceutical inc
  • Sandoz inc
  • Vintage pharmaceuticals inc
  • Watson laboratories inc
  • Abbott laboratories hosp products div
  • Hemopharm usa corp
  • Hospira inc
  • Elkins sinn div ah robins co inc
  • Organon usa inc
  • Abraxis pharmaceutical products
  • App pharmaceuticals llc
  • Bedford laboratories
  • International medication systems ltd
  • Teva parenteral medicines inc
Packagers
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionintramuscular; intravenous125 mg/2mL
Injection, powder, lyophilized, for solutionintramuscular; intravenous40 mg/mL
Injection, suspensionintra-articular; intralesional; intramuscular; soft tissue40 mg/mL
Injection, suspensionintra-articular; intralesional; intramuscular; soft tissue80 mg/mL
Injection, suspensionintralesional; intramuscular; intrasynovial; soft tissue20 mg/mL
Injection, suspensionintramuscular40 mg/1
Injection, suspensionintramuscular40 mg/mL
Injection, suspensionintramuscular80 mg/mL
Suspensionintra-articular; intralesional; intramuscular; intrasynovial20 mg
Suspensionintra-articular; intralesional; intramuscular; intrasynovial80 mg
Suspensionintra-articular; intralesional; intramuscular; intrasynovial40 mg
Solutionintra-articular; intrabursal
Geltopical10 mg/g
Tabletoral2 mg/1
Tabletoral32 mg/1
Tabletoral16 mg
Tabletoral4 mg
Creamtopical2.5 mg
Tabletoral16 mg/1
Tabletoral4 mg/1
Tabletoral8 mg/1
Injection, suspensionintra-articular; intralesional; intramuscular; parenteral; soft tissue40 mg/mL
Injection, suspensionintra-articular; intralesional; intramuscular; parenteral; soft tissue80 mg/mL
Injection, suspensionintralesional; intramuscular; intrasynovial; soft tissue40 mg/mL
Injection, suspensionintralesional; intramuscular; intrasynovial; soft tissue80 mg/mL
Injection, suspensionintramuscular; intrasynovial; soft tissue40 mg/mL
Suspensionintra-articular; intramuscular; intrasynovial; soft tissue injection40 mg
Suspensionintra-articular; intramuscular; intrasynovial; soft tissue injection80 mg
Injection, powder, lyophilized, for solutionintramuscular; intravenous1 g/16mL
Injection, powder, lyophilized, for solutionintramuscular; intravenous125 mg/1
Injection, powder, lyophilized, for solutionintramuscular; intravenous2 g/1
Injection, powder, lyophilized, for solutionintramuscular; intravenous40 mg/1
Injection, powder, lyophilized, for solutionintramuscular; intravenous500 mg/1
Powder for solutionintramuscular; intravenous1 g
Powder for solutionintramuscular; intravenous125 mg
Powder for solutionintramuscular; intravenous40 mg
Powder for solutionintramuscular; intravenous5 g
Powder for solutionintramuscular; intravenous500 mg
Powder for solutionintramuscular; intravenous
Creamtopical
Lotiontopical
Kit
Kitepidural; infiltration; intramuscular; intrasynovial; soft tissue; topical
Kitepidural; infiltration; intra-articular; intralesional; intramuscular; soft tissue
Injection, powder, for solutionintramuscular; intravenous1 g/mL
Injection, powder, for solutionintramuscular; intravenous125 mg/mL
Injection, powder, for solutionintramuscular; intravenous40 mg/mL
Injection, powder, for solutionintramuscular; intravenous500 mg/mL
Injection, powder, for solutionintravenous1 g/1
Injection, powder, for solutionintravenous40 mg/1
Kit
Kit; powderintramuscular; intravenous1 g
Kit; powderintramuscular; intravenous125 mg
Kit; powderintramuscular; intravenous40 mg
Kit; powderintramuscular; intravenous500 mg
Kit; powder for solutionintramuscular; intravenous1 g
Kit; powder for solutionintramuscular; intravenous125 mg
Kit; powder for solutionintramuscular; intravenous40 mg
Kit; powder for solutionintramuscular; intravenous500 mg
Powder, for solutionintravenous125 mg/mL
Powder for solutionintramuscular; intravenous; rectal125 mg
Powder for solutionintramuscular; intravenous; rectal40 mg
Prices
Unit descriptionCostUnit
Methylprednisolone powder96.25USD g
Methylprednisolone ac powdr40.09USD g
Methylprednisolone ss 1 gm vial31.2USD vial
Solu-medrol 1 gm vial24.43USD vial
Solu-medrol (pf) 500 mg vial20.9USD vial
MethylPREDNISolone (Pak) 21 4 mg tablet Disp Pack16.99USD disp
Methylprednisolone 500 mg vial15.6USD vial
Solu-medrol 500 mg vial12.9USD vial
Depo-medrol 80 mg/ml vial11.67USD ml
Methylprednisolone 125 mg vial10.0USD vial
Methylprednisolone 80 mg/ml vial9.12USD ml
Depo-medrol 40 mg/ml vial6.41USD ml
Solu-medrol (pf) 125 mg vial5.83USD vial
Methylprednisolone 40 mg/ml vial5.22USD ml
Medrol 32 mg tablet5.13USD tablet
Methylprednisolone 32 mg tablet4.62USD tablet
Depo-medrol 20 mg/ml vial3.78USD ml
Methylprednisolone 16 mg tablet3.17USD tablet
Methylprednisolone 40 mg vial3.0USD vial
A-methapred 40 mg vial2.36USD vial
Medrol 16 mg tablet2.28USD tablet
Medrol 8 mg tablet2.23USD tablet
Methylprednisolone 8 mg tablet1.74USD tablet
Methylprednisolone 4 mg tablet1.68USD tablet
Medrol 4 mg dosepak1.59USD each
Medrol 4 mg tablet0.99USD tablet
Medrol 2 mg tablet0.84USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point232.5 °CPhysProp
water solubility120 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.5Not Available
logS-2.99ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.109 mg/mLALOGPS
logP2.06ALOGPS
logP1.56ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)12.58ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area94.83 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity103.04 m3·mol-1ChemAxon
Polarizability40.84 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Klaus Annen, Karl Petzoldt, Henry Laurent, Rudolf Wiechert, Helmut Hofmeister, “Novel 6.alpha.-methylprednisolone derivatives, their preparation, and their use.” U.S. Patent US4587236, issued March, 1973.

US4587236
General References
  1. Sloka JS, Stefanelli M: The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult Scler. 2005 Aug;11(4):425-32. [PubMed:16042225 ]
External Links
ATC CodesD07CA02S01CA08D07AA01H02AB04D10AA02H02BX01
AHFS Codes
  • 68:04.00
PDB EntriesNot Available
FDA labelDownload (244 KB)
MSDSDownload (72.6 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with 1,10-Phenanthroline.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Methylprednisolone.
AcetaminophenThe serum concentration of Methylprednisolone can be increased when it is combined with Acetaminophen.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Methylprednisolone.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Methylprednisolone.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Methylprednisolone.
AfatinibThe serum concentration of Methylprednisolone can be increased when it is combined with Afatinib.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Methylprednisolone.
AlbendazoleThe serum concentration of Methylprednisolone can be increased when it is combined with Albendazole.
AldesleukinMethylprednisolone may decrease the antineoplastic activities of Aldesleukin.
AldosteroneThe serum concentration of Methylprednisolone can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Methylprednisolone can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Methylprednisolone can be increased when it is combined with Alfentanil.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Methylprednisolone.
Aluminum hydroxideThe bioavailability of Methylprednisolone can be decreased when combined with Aluminum hydroxide.
Aluminum phosphateThe bioavailability of Methylprednisolone can be decreased when combined with Aluminum phosphate.
AmantadineThe serum concentration of Methylprednisolone can be increased when it is combined with Amantadine.
AmbenoniumThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Ambenonium.
Aminohippuric acidThe serum concentration of Methylprednisolone can be increased when it is combined with Aminohippuric acid.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Methylprednisolone.
AmiodaroneThe serum concentration of Methylprednisolone can be decreased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Methylprednisolone can be increased when it is combined with Amitriptyline.
AmlodipineThe serum concentration of Methylprednisolone can be increased when it is combined with Amlodipine.
Amphotericin BMethylprednisolone may increase the hypokalemic activities of Amphotericin B.
AmprenavirThe serum concentration of Methylprednisolone can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Methylprednisolone can be increased when it is combined with Amsacrine.
AprepitantThe serum concentration of Methylprednisolone can be increased when it is combined with Aprepitant.
AstemizoleThe serum concentration of Methylprednisolone can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Methylprednisolone can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Methylprednisolone can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Methylprednisolone can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Methylprednisolone can be increased when it is combined with Atorvastatin.
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Methylprednisolone.
AzelastineThe serum concentration of Methylprednisolone can be increased when it is combined with Azelastine.
AzithromycinThe serum concentration of Methylprednisolone can be increased when it is combined with Azithromycin.
BazedoxifeneThe serum concentration of Methylprednisolone can be increased when it is combined with Bazedoxifene.
BendroflumethiazideMethylprednisolone may increase the hypokalemic activities of Bendroflumethiazide.
BenzocaineThe serum concentration of Methylprednisolone can be increased when it is combined with Benzocaine.
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Methylprednisolone.
BepridilThe serum concentration of Methylprednisolone can be increased when it is combined with Bepridil.
BevacizumabBevacizumab may increase the cardiotoxic activities of Methylprednisolone.
BexaroteneThe serum concentration of Methylprednisolone can be decreased when it is combined with Bexarotene.
BiperidenThe serum concentration of Methylprednisolone can be increased when it is combined with Biperiden.
Bismuth SubcitrateThe bioavailability of Methylprednisolone can be decreased when combined with Bismuth Subcitrate.
BoceprevirThe serum concentration of Methylprednisolone can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Methylprednisolone can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Methylprednisolone can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Methylprednisolone can be increased when it is combined with Bosutinib.
BromocriptineThe serum concentration of Methylprednisolone can be increased when it is combined with Bromocriptine.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Methylprednisolone.
BumetanideMethylprednisolone may increase the hypokalemic activities of Bumetanide.
BuprenorphineThe serum concentration of Methylprednisolone can be increased when it is combined with Buprenorphine.
BuspironeThe serum concentration of Methylprednisolone can be increased when it is combined with Buspirone.
CabazitaxelThe serum concentration of Methylprednisolone can be increased when it is combined with Cabazitaxel.
CaffeineThe serum concentration of Methylprednisolone can be increased when it is combined with Caffeine.
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Methylprednisolone.
Calcium carbonateThe bioavailability of Methylprednisolone can be decreased when combined with Calcium carbonate.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Methylprednisolone.
CanagliflozinThe serum concentration of Methylprednisolone can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Methylprednisolone can be increased when it is combined with Candesartan.
CaptoprilThe serum concentration of Methylprednisolone can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Methylprednisolone can be decreased when it is combined with Carbamazepine.
CarvedilolThe serum concentration of Methylprednisolone can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Methylprednisolone can be increased when it is combined with Caspofungin.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Methylprednisolone.
CeritinibThe serum concentration of Methylprednisolone can be increased when it is combined with Ceritinib.
CeritinibMethylprednisolone may increase the hyperglycemic activities of Ceritinib.
ChloroquineThe serum concentration of Methylprednisolone can be increased when it is combined with Chloroquine.
ChlorothiazideMethylprednisolone may increase the hypokalemic activities of Chlorothiazide.
ChlorotrianiseneThe serum concentration of Methylprednisolone can be increased when it is combined with Chlorotrianisene.
ChlorpromazineThe serum concentration of Methylprednisolone can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Methylprednisolone.
ChlorpropamideThe serum concentration of Methylprednisolone can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Methylprednisolone can be increased when it is combined with Chlorprothixene.
ChlorthalidoneMethylprednisolone may increase the hypokalemic activities of Chlorthalidone.
CholesterolThe serum concentration of Methylprednisolone can be increased when it is combined with Cholesterol.
CholestyramineCholestyramine can cause a decrease in the absorption of Methylprednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cholic AcidThe serum concentration of Methylprednisolone can be decreased when it is combined with Cholic Acid.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Methylprednisolone.
CilazaprilThe serum concentration of Methylprednisolone can be increased when it is combined with Cilazapril.
CimetidineThe serum concentration of Methylprednisolone can be decreased when it is combined with Cimetidine.
CiprofloxacinThe serum concentration of Methylprednisolone can be increased when it is combined with Ciprofloxacin.
CitalopramThe serum concentration of Methylprednisolone can be increased when it is combined with Citalopram.
ClarithromycinThe serum concentration of Methylprednisolone can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Methylprednisolone can be decreased when combined with Clemastine.
ClofazimineThe serum concentration of Methylprednisolone can be increased when it is combined with Clofazimine.
ClomipramineThe serum concentration of Methylprednisolone can be increased when it is combined with Clomipramine.
ClotrimazoleThe metabolism of Methylprednisolone can be decreased when combined with Clotrimazole.
CobicistatThe serum concentration of Methylprednisolone can be increased when it is combined with Cobicistat.
ColchicineThe serum concentration of Methylprednisolone can be increased when it is combined with Colchicine.
ColesevelamColesevelam can cause a decrease in the absorption of Methylprednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Methylprednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColforsinThe serum concentration of Methylprednisolone can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Methylprednisolone can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Methylprednisolone can be increased when it is combined with Conjugated Equine Estrogens.
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Methylprednisolone.
CoumaphosThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Coumaphos.
CrizotinibThe metabolism of Methylprednisolone can be decreased when combined with Crizotinib.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Methylprednisolone.
CyclosporineThe serum concentration of Methylprednisolone can be increased when it is combined with Cyclosporine.
DabrafenibThe serum concentration of Methylprednisolone can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Methylprednisolone can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Methylprednisolone can be increased when it is combined with Dactinomycin.
DarunavirThe serum concentration of Methylprednisolone can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Methylprednisolone can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Methylprednisolone can be decreased when it is combined with Daunorubicin.
DecamethoniumThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Decamethonium.
DeferasiroxThe serum concentration of Methylprednisolone can be decreased when it is combined with Deferasirox.
DeferasiroxThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Deferasirox.
DelavirdineThe metabolism of Methylprednisolone can be decreased when combined with Delavirdine.
DemecariumThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Demecarium.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Methylprednisolone.
DesipramineThe serum concentration of Methylprednisolone can be increased when it is combined with Desipramine.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Methylprednisolone.
DesloratadineThe serum concentration of Methylprednisolone can be increased when it is combined with Desloratadine.
DexamethasoneThe serum concentration of Methylprednisolone can be decreased when it is combined with Dexamethasone.
DextromethorphanThe serum concentration of Methylprednisolone can be increased when it is combined with Dextromethorphan.
DichlorvosThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Dichlorvos.
DiclofenacThe serum concentration of Methylprednisolone can be increased when it is combined with Diclofenac.
DienestrolThe serum concentration of Methylprednisolone can be increased when it is combined with Dienestrol.
DiethylstilbestrolThe serum concentration of Methylprednisolone can be increased when it is combined with Diethylstilbestrol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Methylprednisolone.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Methylprednisolone.
DigoxinDigoxin may decrease the cardiotoxic activities of Methylprednisolone.
DihydroergotamineThe metabolism of Methylprednisolone can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneMethylprednisolone may increase the fluid retaining activities of Dihydrotestosterone.
DiltiazemThe metabolism of Methylprednisolone can be decreased when combined with Diltiazem.
DipyridamoleThe serum concentration of Methylprednisolone can be increased when it is combined with Dipyridamole.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Methylprednisolone.
DonepezilThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Donepezil.
DoxazosinThe serum concentration of Methylprednisolone can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Methylprednisolone can be increased when it is combined with Doxepin.
DoxorubicinThe serum concentration of Methylprednisolone can be decreased when it is combined with Doxorubicin.
DoxycyclineThe metabolism of Methylprednisolone can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Methylprednisolone can be increased when it is combined with Dronabinol.
DronedaroneThe metabolism of Methylprednisolone can be decreased when combined with Dronedarone.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Methylprednisolone.
EchothiophateThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Echothiophate.
EdrophoniumThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Edrophonium.
EfavirenzThe serum concentration of Methylprednisolone can be decreased when it is combined with Efavirenz.
ElbasvirThe serum concentration of Methylprednisolone can be increased when it is combined with Elbasvir.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Methylprednisolone.
EnalaprilThe serum concentration of Methylprednisolone can be increased when it is combined with Enalapril.
EnzalutamideThe serum concentration of Methylprednisolone can be increased when it is combined with Enzalutamide.
ErgonovineThe serum concentration of Methylprednisolone can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Methylprednisolone can be increased when it is combined with Ergotamine.
ErythromycinThe metabolism of Methylprednisolone can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Methylprednisolone can be decreased when it is combined with Eslicarbazepine acetate.
EstradiolThe serum concentration of Methylprednisolone can be increased when it is combined with Estradiol.
EstramustineThe serum concentration of Methylprednisolone can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Methylprednisolone can be increased when it is combined with Estriol.
EstroneThe serum concentration of Methylprednisolone can be increased when it is combined with Estrone.
Etacrynic acidMethylprednisolone may increase the hypokalemic activities of Etacrynic acid.
Ethinyl EstradiolThe serum concentration of Methylprednisolone can be increased when it is combined with Ethinyl Estradiol.
EtoposideThe serum concentration of Methylprednisolone can be increased when it is combined with Etoposide.
EtravirineThe serum concentration of Methylprednisolone can be decreased when it is combined with Etravirine.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Methylprednisolone.
FelodipineThe serum concentration of Methylprednisolone can be increased when it is combined with Felodipine.
FentanylThe serum concentration of Methylprednisolone can be increased when it is combined with Fentanyl.
FenthionThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Fenthion.
FexofenadineThe serum concentration of Methylprednisolone can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Methylprednisolone can be increased when it is combined with Fidaxomicin.
FingolimodMethylprednisolone may increase the immunosuppressive activities of Fingolimod.
FluconazoleThe metabolism of Methylprednisolone can be decreased when combined with Fluconazole.
FluoxetineThe serum concentration of Methylprednisolone can be increased when it is combined with Fluoxetine.
FluoxymesteroneMethylprednisolone may increase the fluid retaining activities of Fluoxymesterone.
FlupentixolThe serum concentration of Methylprednisolone can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Methylprednisolone can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Methylprednisolone can be increased when it is combined with Flurazepam.
FluvoxamineThe metabolism of Methylprednisolone can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Methylprednisolone can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Methylprednisolone can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Methylprednisolone can be decreased when it is combined with Fosphenytoin.
FurosemideMethylprednisolone may increase the hypokalemic activities of Furosemide.
Fusidic AcidThe serum concentration of Methylprednisolone can be increased when it is combined with Fusidic Acid.
GalantamineThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Gallamine Triethiodide.
GefitinibThe serum concentration of Methylprednisolone can be increased when it is combined with Gefitinib.
GenisteinThe serum concentration of Methylprednisolone can be increased when it is combined with Genistein.
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Ginkgo biloba.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Methylprednisolone.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Methylprednisolone.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Methylprednisolone.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Methylprednisolone.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Methylprednisolone.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Methylprednisolone.
GlyburideThe serum concentration of Methylprednisolone can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Methylprednisolone can be increased when it is combined with Glycerol.
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Methylprednisolone.
Gramicidin DThe serum concentration of Methylprednisolone can be increased when it is combined with Gramicidin D.
GrepafloxacinThe serum concentration of Methylprednisolone can be increased when it is combined with Grepafloxacin.
HaloperidolThe serum concentration of Methylprednisolone can be increased when it is combined with Haloperidol.
HexestrolThe serum concentration of Methylprednisolone can be increased when it is combined with Hexestrol.
Huperzine AThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Huperzine A.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methylprednisolone.
HydrochlorothiazideMethylprednisolone may increase the hypokalemic activities of Hydrochlorothiazide.
HydrocortisoneThe serum concentration of Methylprednisolone can be increased when it is combined with Hydrocortisone.
HydroflumethiazideMethylprednisolone may increase the hypokalemic activities of Hydroflumethiazide.
IdelalisibThe serum concentration of Methylprednisolone can be increased when it is combined with Idelalisib.
ImatinibThe metabolism of Methylprednisolone can be decreased when combined with Imatinib.
ImipramineThe serum concentration of Methylprednisolone can be increased when it is combined with Imipramine.
IndacaterolIndacaterol may increase the hypokalemic activities of Methylprednisolone.
IndapamideMethylprednisolone may increase the hypokalemic activities of Indapamide.
IndinavirThe serum concentration of Methylprednisolone can be decreased when it is combined with Indinavir.
IndomethacinThe serum concentration of Methylprednisolone can be increased when it is combined with Indomethacin.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Methylprednisolone.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Methylprednisolone.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Methylprednisolone.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Methylprednisolone.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Methylprednisolone.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Methylprednisolone.
IsavuconazoniumThe metabolism of Methylprednisolone can be decreased when combined with Isavuconazonium.
IsoflurophateThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Isoflurophate.
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Methylprednisolone.
IsradipineThe metabolism of Methylprednisolone can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Methylprednisolone can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Methylprednisolone can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Methylprednisolone can be increased when it is combined with Ivermectin.
KetamineThe serum concentration of Methylprednisolone can be increased when it is combined with Ketamine.
KetoconazoleThe serum concentration of Methylprednisolone can be increased when it is combined with Ketoconazole.
LansoprazoleThe serum concentration of Methylprednisolone can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Methylprednisolone can be increased when it is combined with Lapatinib.
LeflunomideThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Leflunomide.
LevofloxacinThe serum concentration of Methylprednisolone can be increased when it is combined with Levofloxacin.
LevothyroxineThe serum concentration of Methylprednisolone can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Methylprednisolone can be increased when it is combined with Lidocaine.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Methylprednisolone.
LiothyronineThe serum concentration of Methylprednisolone can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Methylprednisolone can be decreased when it is combined with Liotrix.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Methylprednisolone.
LisinoprilThe serum concentration of Methylprednisolone can be increased when it is combined with Lisinopril.
LomitapideThe serum concentration of Methylprednisolone can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Methylprednisolone can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Methylprednisolone can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Methylprednisolone can be increased when it is combined with Loratadine.
LosartanThe serum concentration of Methylprednisolone can be increased when it is combined with Losartan.
LovastatinThe metabolism of Methylprednisolone can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Methylprednisolone can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Methylprednisolone can be decreased when it is combined with Lumacaftor.
MagaldrateThe bioavailability of Methylprednisolone can be decreased when combined with Magaldrate.
Magnesium carbonateThe bioavailability of Methylprednisolone can be decreased when combined with Magnesium carbonate.
Magnesium hydroxideThe bioavailability of Methylprednisolone can be decreased when combined with Magnesium hydroxide.
Magnesium oxideThe bioavailability of Methylprednisolone can be decreased when combined with Magnesium oxide.
Magnesium TrisilicateThe bioavailability of Methylprednisolone can be decreased when combined with Magnesium Trisilicate.
MalathionThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Malathion.
MaprotilineThe serum concentration of Methylprednisolone can be increased when it is combined with Maprotiline.
MebendazoleThe serum concentration of Methylprednisolone can be increased when it is combined with Mebendazole.
MefloquineThe serum concentration of Methylprednisolone can be increased when it is combined with Mefloquine.
MefloquineThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Mefloquine.
Megestrol acetateThe serum concentration of Methylprednisolone can be increased when it is combined with Megestrol acetate.
MemantineThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Memantine.
MeprobamateThe serum concentration of Methylprednisolone can be increased when it is combined with Meprobamate.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Methylprednisolone.
MestranolThe serum concentration of Methylprednisolone can be increased when it is combined with Mestranol.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Methylprednisolone.
MethadoneThe serum concentration of Methylprednisolone can be increased when it is combined with Methadone.
MethyclothiazideMethylprednisolone may increase the hypokalemic activities of Methyclothiazide.
MethyltestosteroneMethylprednisolone may increase the fluid retaining activities of Methyltestosterone.
MetolazoneMethylprednisolone may increase the hypokalemic activities of Metolazone.
MetoprololThe serum concentration of Methylprednisolone can be increased when it is combined with Metoprolol.
MibefradilThe serum concentration of Methylprednisolone can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Methylprednisolone can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Methylprednisolone can be decreased when it is combined with Midazolam.
MifepristoneThe therapeutic efficacy of Methylprednisolone can be decreased when used in combination with Mifepristone.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Methylprednisolone.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Methylprednisolone.
MinaprineThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Minaprine.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Methylprednisolone.
MitomycinThe serum concentration of Methylprednisolone can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Methylprednisolone can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Methylprednisolone can be decreased when it is combined with Mitoxantrone.
MivacuriumMivacurium may increase the adverse neuromuscular activities of Methylprednisolone.
ModafinilThe serum concentration of Methylprednisolone can be decreased when it is combined with Modafinil.
MorphineThe serum concentration of Methylprednisolone can be increased when it is combined with Morphine.
NafcillinThe serum concentration of Methylprednisolone can be decreased when it is combined with Nafcillin.
NaltrexoneThe serum concentration of Methylprednisolone can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Methylprednisolone can be increased when it is combined with Naringenin.
NatalizumabThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Natalizumab.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Methylprednisolone.
NefazodoneThe serum concentration of Methylprednisolone can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Methylprednisolone can be decreased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Methylprednisolone can be increased when it is combined with Neostigmine.
NeostigmineThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Neostigmine.
NetupitantThe serum concentration of Methylprednisolone can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Methylprednisolone can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Methylprednisolone can be increased when it is combined with Nicardipine.
NicorandilThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Nicorandil.
NifedipineThe serum concentration of Methylprednisolone can be decreased when it is combined with Nifedipine.
NilotinibThe metabolism of Methylprednisolone can be decreased when combined with Nilotinib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Methylprednisolone.
NisoldipineThe serum concentration of Methylprednisolone can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Methylprednisolone can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Methylprednisolone can be increased when it is combined with Nitrendipine.
NorethisteroneThe serum concentration of Methylprednisolone can be decreased when it is combined with Norethisterone.
OlaparibThe metabolism of Methylprednisolone can be decreased when combined with Olaparib.
OmeprazoleThe serum concentration of Methylprednisolone can be increased when it is combined with Omeprazole.
OsimertinibThe serum concentration of Methylprednisolone can be increased when it is combined with Osimertinib.
OuabainOuabain may decrease the cardiotoxic activities of Methylprednisolone.
OxandroloneMethylprednisolone may increase the fluid retaining activities of Oxandrolone.
OxymetholoneMethylprednisolone may increase the fluid retaining activities of Oxymetholone.
P-NitrophenolThe serum concentration of Methylprednisolone can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Methylprednisolone can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Methylprednisolone can be increased when it is combined with Palbociclib.
Palmitic AcidThe serum concentration of Methylprednisolone can be increased when it is combined with Palmitic Acid.
PantoprazoleThe serum concentration of Methylprednisolone can be increased when it is combined with Pantoprazole.
ParoxetineThe serum concentration of Methylprednisolone can be increased when it is combined with Paroxetine.
PentobarbitalThe serum concentration of Methylprednisolone can be decreased when it is combined with Pentobarbital.
PerindoprilThe serum concentration of Methylprednisolone can be increased when it is combined with Perindopril.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Methylprednisolone.
PhenobarbitalThe serum concentration of Methylprednisolone can be decreased when it is combined with Phenobarbital.
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Methylprednisolone.
PhenytoinThe serum concentration of Methylprednisolone can be decreased when it is combined with Phenytoin.
PhysostigmineThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Physostigmine.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Methylprednisolone.
PimozideThe serum concentration of Methylprednisolone can be increased when it is combined with Pimozide.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Methylprednisolone.
PiretanideMethylprednisolone may increase the hypokalemic activities of Piretanide.
Platelet Activating FactorThe serum concentration of Methylprednisolone can be decreased when it is combined with Platelet Activating Factor.
Polyestradiol phosphateThe serum concentration of Methylprednisolone can be increased when it is combined with Polyestradiol phosphate.
PolythiazideMethylprednisolone may increase the hypokalemic activities of Polythiazide.
PonatinibThe serum concentration of Methylprednisolone can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Methylprednisolone can be increased when it is combined with Posaconazole.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Methylprednisolone.
PravastatinThe serum concentration of Methylprednisolone can be increased when it is combined with Pravastatin.
PrazosinThe serum concentration of Methylprednisolone can be increased when it is combined with Prazosin.
PrednisoneThe serum concentration of Methylprednisolone can be increased when it is combined with Prednisone.
PrimidoneThe serum concentration of Methylprednisolone can be decreased when it is combined with Primidone.
ProbenecidThe serum concentration of Methylprednisolone can be increased when it is combined with Probenecid.
ProgesteroneThe serum concentration of Methylprednisolone can be decreased when it is combined with Progesterone.
PromethazineThe serum concentration of Methylprednisolone can be increased when it is combined with Promethazine.
PropafenoneThe serum concentration of Methylprednisolone can be increased when it is combined with Propafenone.
PropranololThe serum concentration of Methylprednisolone can be increased when it is combined with Propranolol.
ProtriptylineThe serum concentration of Methylprednisolone can be increased when it is combined with Protriptyline.
PyridostigmineThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Pyridostigmine.
QuercetinThe serum concentration of Methylprednisolone can be increased when it is combined with Quercetin.
QuinacrineThe serum concentration of Methylprednisolone can be increased when it is combined with Quinacrine.
QuinestrolThe serum concentration of Methylprednisolone can be increased when it is combined with Quinestrol.
QuinethazoneMethylprednisolone may increase the hypokalemic activities of Quinethazone.
QuinidineThe serum concentration of Methylprednisolone can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Methylprednisolone can be increased when it is combined with Quinine.
Rabies vaccineThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Rabies vaccine.
RanitidineThe serum concentration of Methylprednisolone can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Methylprednisolone can be increased when it is combined with Ranolazine.
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Methylprednisolone.
ReboxetineThe serum concentration of Methylprednisolone can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Methylprednisolone can be increased when it is combined with Regorafenib.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Methylprednisolone.
ReserpineThe serum concentration of Methylprednisolone can be decreased when it is combined with Reserpine.
RifabutinThe serum concentration of Methylprednisolone can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Methylprednisolone can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Methylprednisolone can be decreased when it is combined with Rifapentine.
RilpivirineThe serum concentration of Methylprednisolone can be increased when it is combined with Rilpivirine.
RitonavirThe serum concentration of Methylprednisolone can be decreased when it is combined with Ritonavir.
RivastigmineThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Rivastigmine.
RoflumilastRoflumilast may increase the immunosuppressive activities of Methylprednisolone.
RolapitantThe serum concentration of Methylprednisolone can be increased when it is combined with Rolapitant.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Methylprednisolone.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Methylprednisolone.
SaquinavirThe serum concentration of Methylprednisolone can be decreased when it is combined with Saquinavir.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Methylprednisolone.
ScopolamineThe serum concentration of Methylprednisolone can be increased when it is combined with Scopolamine.
SelegilineThe serum concentration of Methylprednisolone can be increased when it is combined with Selegiline.
SertralineThe serum concentration of Methylprednisolone can be increased when it is combined with Sertraline.
SildenafilThe metabolism of Methylprednisolone can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Methylprednisolone can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Methylprednisolone can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Methylprednisolone can be increased when it is combined with Simvastatin.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Methylprednisolone.
SirolimusThe serum concentration of Methylprednisolone can be decreased when it is combined with Sirolimus.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Methylprednisolone.
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Methylprednisolone.
SorafenibThe serum concentration of Methylprednisolone can be increased when it is combined with Sorafenib.
SpironolactoneThe serum concentration of Methylprednisolone can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Methylprednisolone can be decreased when it is combined with St. John's Wort.
StanozololMethylprednisolone may increase the fluid retaining activities of Stanozolol.
StaurosporineThe serum concentration of Methylprednisolone can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Methylprednisolone can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Methylprednisolone can be decreased when it is combined with Streptozocin.
SulfinpyrazoneThe serum concentration of Methylprednisolone can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Methylprednisolone can be decreased when combined with Sulfisoxazole.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Methylprednisolone.
SumatriptanThe serum concentration of Methylprednisolone can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Methylprednisolone can be increased when it is combined with Sunitinib.
Synthetic Conjugated Estrogens, AThe serum concentration of Methylprednisolone can be increased when it is combined with Synthetic Conjugated Estrogens, A.
Synthetic Conjugated Estrogens, BThe serum concentration of Methylprednisolone can be increased when it is combined with Synthetic Conjugated Estrogens, B.
TacrineThe serum concentration of Methylprednisolone can be increased when it is combined with Tacrine.
TacrineThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Tacrine.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Methylprednisolone.
TamoxifenThe serum concentration of Methylprednisolone can be decreased when it is combined with Tamoxifen.
Taurocholic AcidThe serum concentration of Methylprednisolone can be increased when it is combined with Taurocholic Acid.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Methylprednisolone.
TelaprevirThe serum concentration of Methylprednisolone can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Methylprednisolone can be increased when it is combined with Telithromycin.
TelmisartanThe serum concentration of Methylprednisolone can be increased when it is combined with Telmisartan.
TemsirolimusThe serum concentration of Methylprednisolone can be increased when it is combined with Temsirolimus.
TerazosinThe serum concentration of Methylprednisolone can be increased when it is combined with Terazosin.
TerfenadineThe serum concentration of Methylprednisolone can be increased when it is combined with Terfenadine.
TesmilifeneThe serum concentration of Methylprednisolone can be decreased when it is combined with Tesmilifene.
TestosteroneMethylprednisolone may increase the fluid retaining activities of Testosterone.
TestosteroneThe serum concentration of Methylprednisolone can be increased when it is combined with Testosterone.
TiboloneThe serum concentration of Methylprednisolone can be increased when it is combined with Tibolone.
TicagrelorThe serum concentration of Methylprednisolone can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Methylprednisolone can be decreased when combined with Ticlopidine.
TocilizumabThe serum concentration of Methylprednisolone can be decreased when it is combined with Tocilizumab.
TofacitinibMethylprednisolone may increase the immunosuppressive activities of Tofacitinib.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Methylprednisolone.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Methylprednisolone.
TolvaptanThe serum concentration of Methylprednisolone can be increased when it is combined with Tolvaptan.
TorasemideMethylprednisolone may increase the hypokalemic activities of Torasemide.
TrastuzumabTrastuzumab may increase the neutropenic activities of Methylprednisolone.
TrazodoneThe serum concentration of Methylprednisolone can be decreased when it is combined with Trazodone.
TrichlorfonThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Trichlorfon.
TrichlormethiazideMethylprednisolone may increase the hypokalemic activities of Trichlormethiazide.
TrifluoperazineThe serum concentration of Methylprednisolone can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Methylprednisolone can be increased when it is combined with Triflupromazine.
TrimethoprimThe serum concentration of Methylprednisolone can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Methylprednisolone can be increased when it is combined with Trimipramine.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Methylprednisolone.
TroleandomycinThe serum concentration of Methylprednisolone can be increased when it is combined with Troleandomycin.
TubocurarineThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Tubocurarine.
VenlafaxineThe metabolism of Methylprednisolone can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Methylprednisolone can be decreased when combined with Verapamil.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Methylprednisolone.
VinblastineThe serum concentration of Methylprednisolone can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Methylprednisolone can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Methylprednisolone can be increased when it is combined with Vinorelbine.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Methylprednisolone.
VoriconazoleThe serum concentration of Methylprednisolone can be increased when it is combined with Voriconazole.
WarfarinMethylprednisolone may increase the anticoagulant activities of Warfarin.
ZeranolThe serum concentration of Methylprednisolone can be increased when it is combined with Zeranol.
ZimelidineThe serum concentration of Methylprednisolone can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Methylprednisolone can be decreased when combined with Ziprasidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Owen HC, Miner JN, Ahmed SF, Farquharson C: The growth plate sparing effects of the selective glucocorticoid receptor modulator, AL-438. Mol Cell Endocrinol. 2007 Jan 29;264(1-2):164-70. Epub 2006 Dec 19. [PubMed:17182172 ]
  2. Juruena MF, Cleare AJ, Papadopoulos AS, Poon L, Lightman S, Pariante CM: Different responses to dexamethasone and prednisolone in the same depressed patients. Psychopharmacology (Berl). 2006 Dec;189(2):225-35. Epub 2006 Oct 3. [PubMed:17016711 ]
  3. Boivin MA, Ye D, Kennedy JC, Al-Sadi R, Shepela C, Ma TY: Mechanism of glucocorticoid regulation of the intestinal tight junction barrier. Am J Physiol Gastrointest Liver Physiol. 2007 Feb;292(2):G590-8. Epub 2006 Oct 26. [PubMed:17068119 ]
  4. Quesnell RR, Han X, Schultz BD: Glucocorticoids stimulate ENaC upregulation in bovine mammary epithelium. Am J Physiol Cell Physiol. 2007 May;292(5):C1739-45. Epub 2007 Jan 24. [PubMed:17251323 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Oka A, Oda M, Saitoh H, Nakayama A, Takada M, Aungst BJ: Secretory transport of methylprednisolone possibly mediated by P-glycoprotein in Caco-2 cells. Biol Pharm Bull. 2002 Mar;25(3):393-6. [PubMed:11913542 ]
  2. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019 ]
  3. Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803. [PubMed:14661924 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23